VolitionRx Limited (AMEX:VNRX) Prepares for Q1 2026 Earnings: Key Developments and Financial Overview

VolitionRx secured €2 million in non-dilutive funding to advance its Nu.Q product portfolio and regulatory transitions.Recent clinical studies highlight the potential of Nu.Q biomarkers in trauma and lung cancer management.Despite innovative progress, the company reported a net loss of $5.4 million and negative EBITDA of $4.2 million in its latest financials.(AMEX:VNRX) is preparing to announce its quarterly earnings on April 1, 2026. Analysts predict an earnings per share (EPS) of -$0.04, with expected rev ...